Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns."
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns."
